Guardant Health, Inc.
Guardant Health, Inc.
Your view on GH
Overview
What the company does, where it operates, and who runs it.
About Guardant Health, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Helmy Eltoukhy
- Headquarters
- 505 Penobscot Drive, Palo Alto, CA, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Helmy Eltoukhy
- Headquarters
- 505 Penobscot Drive, Palo Alto, CA, US
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.
In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus.
Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions.
The company was incorporated in 2011 and is headquartered in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Guardant Health, Inc. from FRC's valuation model, read against the market price. GH last traded at $144.03; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Guardant Health, Inc.. Starting points for Guardant Health, Inc.: EPS -$3.61, beta 1.66 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Guardant Health, Inc.. Guardant Health, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Guardant Health, Inc.. Trailing twelve-month EPS for Guardant Health, Inc. stands at -$3.61. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$188.16
average of 19 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy20
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.75 | -$0.74 | -$3.41 | -$2.21 |
| Low estimate | -$0.85 | -$0.85 | -$3.54 | -$7.29 |
| High estimate | -$0.58 | -$0.62 | -$3.31 | $9.37 |
| No. of analysts | 11 | 8 | 13 | 13 |
| Year-ago EPS | -$1.00 | -$0.85 | -$3.32 | — |
| Growth | +25.2% | +13.4% | -2.8% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $370.34M | $394.30M | $1.37B | $1.84B |
| Low estimate | $367.21M | $380.42M | $1.36B | $1.79B |
| High estimate | $380.13M | $406.50M | $1.49B | $1.91B |
| No. of analysts | 14 | 10 | 19 | 19 |
| Year-ago revenue | $281.27M | $301.67M | $982.02M | — |
| Growth | +31.7% | +30.7% | +39.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Guardant Health, Inc.. Guardant Health, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- BDSXBiodesix, Inc.Medical - Diagnostics & Research$73M
- BLLNBillionToOne, Inc.Medical - Diagnostics & Research$4.6B
- BNRBurning Rock Biotech LimitedMedical - Diagnostics & Research$14M
- CSTLCastle Biosciences, Inc.Medical - Diagnostics & Research$1.0B
- FLGTFulgent Genetics, Inc.Medical - Diagnostics & Research$673M
- GRALGRAIL, Inc.Medical - Diagnostics & Research$4.7B
- MYGNMyriad Genetics, Inc.Medical - Diagnostics & Research$534M
- NEONeoGenomics, Inc.Medical - Diagnostics & Research$2.0B
More Medical - Diagnostics & Research companies
ETFs holding Guardant Health, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
- VBVanguard Small-Cap ETF$76.9B in assets0.28%
- VBKVanguard Small-Cap Growth ETF$22.8B in assets0.66%
- ARKGARK Genomic Revolution ETF$2.2B in assets5.16%
- LFSCF/M Emerald Life Sciences Innovation ETF$125M in assets4.39%
- PTHInvesco Dorsey Wright Healthcare Momentum ETF$293M in assets3.37%
- IHFiShares US Healthcare Providers ETF$1.5B in assets2.39%
- BBHVanEck Biotech ETF$536M in assets2.38%
Largest holders first, then the funds most concentrated in GH.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Guardant Health, Inc., and how their positions are changing. At a $19.49B market value, institutional positions materially move Guardant Health, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Guardant Health, Inc. executives and directors. Shares of Guardant Health, Inc. have traded between $29.91 and $101.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Guardant Health, Inc.. Guardant Health, Inc. is a $19.49B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Guardant Health, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Guardant Health, Inc.. Coverage tracks Guardant Health, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Guardant Health, Inc.